Gene/Protein Disease Symptom Drug Enzyme Compound
Pivot Concepts:   Target Concepts:
Query: UNIPROT:P61278 (somatostatin)
 22,083 document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)

The physicochemical behaviour of parathyrin on surfaces was investigated. Parathyrin is bound to the wall of polyethylene, polypropylene and flint glass tubes. This adsorptive binding of the hormone, detected by labelled antibodies, is a time-dependent process which is complete within one hour. The addition of plasma decreases but does not prevent adsorption. Coating of the tubes with an anti-N-regional or anti-C-regional antiserum decreases the sensitivity of the detection of 1-34, 53-84 and 1-84 intact parathyrin, when performed in buffer. In the presence of plasma the increase of radiolabelled antibody detecting the parathyrin was more pronounced when tubes were precoated with an anti-parathyrin antibody. The sensitivity of the 1-84 parathyrin assay was also reduced when incubation was carried out in the presence of high concentrations of parathyrin-fragments, calcitonin, somatostatin or bovine serum albumin. Assay specificity seems to be related to the specificity of the labelled antibody for the respective hormonal fragment, not to that of the antibody used for coating the tubes. This investigation illustrates the necessity for the careful control of parathyrin assay conditions, e. g. non-specific binding of native parathyrin and radiolabelled tracers to laboratory reaction vessels.
 ...
PMID:Adsorption of parathyrin: pitfall for solid phase assays using radiolabelled antibodies? 744 Nov 86

Thrombosis of the left subclavian vein occurred in a 44-year-old man. It was found to be caused by an atypical thymus carcinoid of the anterior mediastinum without carcinoid syndrome. Primary resection was not possible, but it was removed after three cycles of neoadjuvant chemotherapy with doxorubicin, cisplatin, vincristine and cyclophosphamide. Increased concentrations of alkaline phosphatase and parathormone were then noted. Subtotal parathyroidectomy revealed hyperplastic parathyroids. A gastrinoma was suspected from a history of peptic ulcer for many years which had persisted despite a Billroth II gastric resection 10 years ago. Serum gastrin, analysis of gastric secretion and a secretin-stimulating test confirmed the diagnosis. Recurrent episodes of weakness and syncope, in the presence of low blood sugar levels and a positive C-peptide suppression test, were interpreted as due to an insulinoma. There was no evidence of increased hypophyseal or adrenal function. Finally, in the absence of a family history, multiple endocrine neoplasia type 1 (MEN 1) was diagnosed with co-existing primary hyperparathyroidism, gastrinoma, insulinoma and thymus carcinoid. Somatostatin-receptor scintigraphy provided localization of the MEN 1 with enrichment in the thorax and abdomen.
 ...
PMID:[Thymus carcinoid in multiple endocrine neoplasms type I]. 790 23

The effect of cadmium (Cd) on the thyroid and parathyroid glands was examined following a 12-week exposure of rats to 5 or 50 mg Cd/dm3. Immunohistochemical methods were used to determine calcitonin (CT), calcitonin-gene related peptide (GGRP), parathormone (PTH), somatostatin (ST), synaptophysin (SPh) and neuron-specific enolase (NSE). Calcium and cadmium concentrations in the femoral bone were assayed. The animals exposed to cadmium showed attenuation of all reactions, which was most distinct after 50 mg Cd/dm3. Exposure-dependent cadmium accumulation and a decrease in calcium concentration in the femoral bone were noted.
 ...
PMID:Preliminary immunohistochemical study of C cells of the thyroid and endocrine cells of the parathyroid glands in rats after prolonged exposure to cadmium. 1137 20

The somatostatin analogue lanreotide is effective in reducing growth hormone levels in patients with acromegaly. Acromegaly is characterized by calcium homeostasis alterations. The aim of our study was to evaluate the effects of lanreotide on bone turnover markers in a group of acromegalic patients and to verify a possible increase of intact parathormone (iPTH) levels in a transient or persistent way. Serum GH, IGF-I and serum and urinary markers of bone metabolism were measured before treatment and on months 3 and 24. In short-term treatment (3 months), lanreotide significantly decreased GH, IGF-I, serum calcium, osteocalcin and alkaline phosphatase levels, but increased iPTH level (49 +/- 16.7 vs pre-treatment 28.3 +/- 7.6 ng/L, p<0.001). During long-term study (24 months) GH and IGF-I were significantly still low; serum calcium and alkaline phosphatase levels returned to pre-treatment levels. iPTH level was significantly still higher compared with pre-treatment (46.4 +/- 9.2 vs 28.3 +/- 7.6 ng/L, p<0.05). No changes were seen in serum albumin, creatinine and vitamin D during short and long term treatment. The changes of most bone markers during lanreotide treatment can be explained by the decrease of GH and IGF-I. The increase of iPTH concentration suggests that lanreotide has ulterior and long-standing actions on calcium homeostasis: intestinal malabsorption of calcium due to the lanreotide could contribute to this "secondary" hyperparathyroidism. The clinical relevance of these long-standing effects needs to be further investigated.
 ...
PMID:Long-term treatment of acromegaly with lanreotide: evidence of increased serum parathormone concentration. 1564 68

We describe a hitherto undocumented variant of dimorphic pituitary neoplasm composed of an admixture of neurosecretory cells and profuse leiomyomatous stroma around intratumoral vessels. Radiologically perceived as a macroadenoma of 3.8 cm in diameter, this pituitary mass developed in an otherwise healthy 43-year-old female. At the term of a yearlong history of amenorrhea and progressive bitemporal visual loss, subtotal resection was performed via transsphenoidal microsurgery. Discounting mild hyperprolactinemia, there was no evidence of excess hormone production. Histologically, solid sheets, nests and cords of epithelial-looking, yet cytokeratin-negative cells were seen growing in a richly vascularized stroma of spindle cells. While strong immunoreactivity for NCAM, Synaptophysin and Chromogranin-A was detected in the former, the latter showed both morphological and immunophenotypic hallmarks of smooth muscle, being positive for vimentin, muscle actin and smooth muscle actin. Architectural patterns varied from monomorphous stroma-dominant zones through biphasic neuroendocrine-leiomyomatous areas, to pseudopapillary fronds along vascular cores. Only endothelia were labeled with CD34. Staining for S100 protein and GFAP, characteristics of sustentacular cells, as well as bcl-2 and c-kit was absent. Except for alpha-subunit, anterior pituitary hormones tested negative in tumor cells, as did a panel of peripheral endocrine markers, including serotonin, somatostatin, calcitonin, parathormone and vasoactive intestinal polypeptide. Mitotic activity was absent and the MIB-1 labeling index low (1-2%). While assignment of this lesion to any established neoplastic entity is not forthcoming, we propose it is being considered as a low-grade neuroendocrine tumor possibly related to null cell adenoma.
 ...
PMID:Leiomyomatoid angiomatous neuroendocrine tumor (LANT) of the pituitary: a distinctive biphasic neoplasm with primitive secretory phenotype and smooth muscle-rich stroma. 1652 Sep 66


<< Previous 1 2